LON:GSK GSK (GSK) Share Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free gsk Stock Alerts GBX 1,780.50 +7.00 (+0.39%) (As of 04:35 PM ET) Add Compare Share Share Today's Range 1,769.99▼ 1,78750-Day Range 1,583.50▼ 1,773.5052-Week Range 1,302.60▼ 1,787Volume6.40 million shsAverage Volume6.92 million shsMarket Capitalization£72.82 billionP/E Ratio1,483.75Dividend Yield3.59%Price TargetGBX 1,675.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability Get GSK alerts: Email Address GSK MarketRank™ Stock AnalysisAnalyst RatingHold2.29 Rating ScoreUpside/Downside5.9% DownsideGBX 1,675.63 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-1.56Upright™ Environmental ScoreNews Sentiment0.42Based on 13 Articles This WeekInsider TradingSelling Shares£231.78 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.71 out of 5 stars 2.1 Analyst's Opinion Consensus RatingGSK has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageGSK has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GSK's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GSK. Previous Next 1.7 Dividend Strength Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about GSK's dividend. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGSK has received a 66.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "HIV medication", "Shingles vaccines", "Mouthwash", "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Clinical research services for the respiratory system" products. See details.Environmental SustainabilityThe Environmental Impact score for GSK is -1.56. Previous Next 1.9 News and Social Media Coverage News SentimentGSK has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for GSK this week, compared to 7 articles on an average week.Search InterestOnly 25 people have searched for GSK on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GSK insiders have sold 31,451.03% more of their company's stock than they have bought. Specifically, they have bought £7,346.04 in company stock and sold £2,317,751.36 in company stock.Percentage Held by InsidersOnly 1.77% of the stock of GSK is held by insiders.Percentage Held by Institutions45.27% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GSK's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 1,483.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 139.60.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 1,483.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 170.75.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.12. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 5.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About GSK Stock (LON:GSK)GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Read More GSK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GSK Stock News HeadlinesMay 9, 2024 | forbes.comBuy Write Grabs Next Week’s Dividend From GSKMay 9, 2024 | finance.yahoo.comGSK (LON:GSK) Is Paying Out A Dividend Of £0.15May 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 9, 2024 | americanbankingnews.comGSK plc (LON:GSK) Receives Average Rating of "Hold" from BrokeragesMay 8, 2024 | americanbankingnews.comGSK's (GSK) Equal Weight Rating Reaffirmed at BarclaysMay 6, 2024 | finance.yahoo.comGSK Stock Today: Buying An August Covered Call Boosts Your Return By This MuchMay 5, 2024 | finance.yahoo.comGSK plc (NYSE:GSK) Q1 2024 Earnings Call TranscriptMay 4, 2024 | americanbankingnews.comGSK (LON:GSK) Price Target Raised to GBX 1,660May 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 3, 2024 | americanbankingnews.comGSK (LON:GSK) Stock Rating Reaffirmed by Shore CapitalMay 3, 2024 | americanbankingnews.comGSK (LON:GSK) Sets New 12-Month High After Dividend AnnouncementMay 2, 2024 | bloomberg.comGSK, Boehringer Put Profits Over User Safety, Zantac Jury ToldMay 2, 2024 | msn.comModerna to seek parity for RSV shot as rivals lead in marketMay 1, 2024 | morningstar.comGSK Lifts Guidance After Turnover Beats Expectations — UpdateMay 1, 2024 | msn.comGSK Non-GAAP EPS of 43.10p, revenue of £7.4B; updates FY24 outlookApril 30, 2024 | finance.yahoo.comGenomics plc and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial designApril 30, 2024 | marketwatch.comGSK Turnover, Net Profit Expected to Rise as Investors Seek Zantac Litigation Clarity -- Earnings PreviewApril 24, 2024 | msn.comSCI, GSK launches $1m initiative to boost immunisation rate in Nigeria, EthiopiaApril 24, 2024 | msn.comUS regulator accepts GSK’s application to expand treatment of cancer drugApril 24, 2024 | ft.comGSK readies for pivotal ruling in Zantac casesApril 19, 2024 | seekingalpha.comGSK Trades At Low Price Multiples, But Its Pipeline Needs To ImproveApril 18, 2024 | finance.yahoo.comGSK Canada expands charitable partnerships to include support of environmental sustainability and STEMApril 16, 2024 | finance.yahoo.comGSK May 2024 28.000 call (GSK240517C00028000)April 16, 2024 | seekingalpha.comLyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data CatalystsApril 16, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwnApril 16, 2024 | lse.co.ukGSK's latest meningitis vaccine accepted for review by US regulatorApril 16, 2024 | markets.businessinsider.comFDA Accepts GSK's 5-in-1 Meningococcal ABCWY Vaccine Candidate For Regulatory ReviewSee More Headlines Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/29/2020Ex-Dividend for 4/11 Dividend2/22/2024Dividend Payable4/11/2024Today5/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolLON:GSK CUSIPN/A CIKN/A Webwww.gsk.com Phone+44-20-80475000FaxN/AEmployees70,212Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 1,675.63 High Stock Price TargetGBX 1,950 Low Stock Price TargetGBX 1,390 Potential Upside/Downside-6.0%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 1.20 Trailing P/E Ratio1,485.00 Forward P/E Ratio11.33 P/E Growth1.12Net Income£4.93 billion Net Margins16.25% Pretax MarginN/A Return on Equity46.38% Return on Assets8.81% Debt Debt-to-Equity Ratio140.82 Current Ratio0.88 Quick Ratio0.73 Sales & Book Value Annual Sales£30.33 billion Price / Sales2.40 Cash FlowGBX 218.77 per share Price / Cash Flow8.15 Book ValueGBX 329 per share Price / Book5.42Miscellaneous Outstanding Shares4,090,000,000Free FloatN/AMarket Cap£72.88 billion OptionableNot Optionable Beta0.27 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Emma Natasha Walmsley (Age 55)CEO & Director Comp: $5.39MMs. Julie Belita Brown (Age 62)CFO & Executive Director Comp: $5.14MMs. Shobie Ramakrishnan (Age 53)Chief Digital & Technology Officer Mr. Tony WoodChief Scientific Officer and Head of R&DMs. Sarah Elton-FarrHead of Investor RelationsMr. James FordSenior VP & Group General Counsel of Legal & ComplianceMs. Sally JacksonSenior Vice President of Global Communications & CEO OfficeMr. David Simon Redfern BSc (Hons) (Age 58)CA, President of Corporate Development Ms. Diana ConradChief People OfficerMr. Philip C. ThomsonPresident of Global AffairsMore ExecutivesKey CompetitorsAstraZenecaLON:AZNHaleonLON:HLNDechra PharmaceuticalsLON:DPHSmith & NephewLON:SNConvaTec GroupLON:CTECView All CompetitorsInsidersUrs RohnerBought 434 shares on 3/20/2024Total: £721,308.00 ($1,662.00/share)Emma WalmsleySold 139,792 sharesTotal: £231.78 M ($1,658.00/share)Emma WalmsleyBought 8 shares on 2/9/2024Total: £13,296.00 ($1,662.00/share)Julie BrownBought 19,360 shares on 2/1/2024Total: £30.65 M ($1,583.00/share)Urs RohnerBought 478 shares on 12/20/2023Total: £693,100.00 ($1,450.00/share)View All Insider Transactions GSK Stock Analysis - Frequently Asked Questions Should I buy or sell GSK stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares. View GSK analyst ratings or view top-rated stocks. What is GSK's stock price target for 2024? 7 analysts have issued 1 year price targets for GSK's stock. Their GSK share price targets range from GBX 1,390 to GBX 1,950. On average, they predict the company's share price to reach GBX 1,675.63 in the next year. This suggests that the stock has a possible downside of 5.9%. View analysts price targets for GSK or view top-rated stocks among Wall Street analysts. How have GSK shares performed in 2024? GSK's stock was trading at GBX 1,450.20 at the start of the year. Since then, GSK shares have increased by 22.8% and is now trading at GBX 1,780.50. View the best growth stocks for 2024 here. How were GSK's earnings last quarter? GSK plc (LON:GSK) issued its earnings results on Wednesday, July, 29th. The company reported $56.90 EPS for the quarter. GSK had a trailing twelve-month return on equity of 46.38% and a net margin of 16.25%. How often does GSK pay dividends? What is the dividend yield for GSK? GSK declared a dividend on Wednesday, May 1st. Stockholders of record on Thursday, May 16th will be given a dividend of GBX 15 per share on Thursday, July 11th. This represents a yield of 0.9%. The ex-dividend date of this dividend is Thursday, May 16th. The official announcement can be accessed at this link. Read our dividend analysis for GSK. Is GSK a good dividend stock? GSK (LON:GSK) pays an annual dividend of GBX 64 per share and currently has a dividend yield of 3.83%. The dividend payout ratio is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for GSK. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD). How do I buy shares of GSK? Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:GSK) was last updated on 5/9/2024 by MarketBeat.com Staff From Our Partners1970’s computer coder Issues Shocking AI WarningInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.